Our Clinical Pipeline

Complex Diseases Require Multiple Routes of Attack

IMV’s current clinical strategy focuses on immuno-oncology therapies with our lead therapeutic candidate, DPX-Survivac, for advanced ovarian cancer and diffuse large B-cell lymphoma (DLBCL). Both of these tumor types are associated with poor outcomes and are thus high unmet medical needs.

We are also currently engaged in combination immunotherapy clinical trials leveraging DPX-Survivac and intermittent low dose cyclophosphamide with Merck’s currently marketed anti-PD-1 drug, pembrolizumab, across multiple indications.

Our clinical program focuses on broadening the utility of next-generation immunotherapies among patient populations with few treatment options.

Our ongoing clinical trials currently include:

• • Recurrent Ovarian Cancer
    ClinicalTrials.gov listing
  • Recurrent Survivin-Expressing DLBCL
    ClinicalTrials.gov listing
  • Selected Advanced and Recurrent Solid Tumors
  • CinicalTrials.gov listing